Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of NS-041 add-on therapy in focal epilepsy
CTR20251874Phase 2Active
- Sponsor
- Nuance Pharma
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NS-041 in Focal Onset Epilepsy, sponsored by Nuance Pharma. Started Jul 2025; status: active.
02
Drugs
NS-041
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on CTR20251874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251874.